Coronary disease & ACSRandomised controlled trial
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial
- Randomised controlled trial
Authors' conclusion
Among high-risk patients undergoing complex PCI, tailored antiplatelet strategy with early escalation and late de-escalation, as compared with dual antiplatelet therapy, did not decrease the incidence of primary net adverse events at 12 months.
Study context
- Population
- High-risk patients (anatomical or clinical characteristics) undergoing complex percutaneous coronary intervention (PCI)
- Participants
- 2,018 patients
- Comparison
- Tailored antiplatelet strategy vs DAPT
- Primary endpoint
- Net adverse events: death from any cause, MI, stroke, stent thrombosis, unplanned urgent revascularization, and clinically relevant bleeding (BARC type 2, 3, or 5)
- Follow-up
- 12 months
Primary result
As reported in the abstract
Hazard ratio
1.19
95% CI 0.90–1.58
P = 0.21
Events by treatment group
Tailored vs DAPT
HR 1.19 (95% CI 0.90–1.58); P = 0.21
Further findings
Major ischaemic events
- Appeared similar in both groups
Safety
| Outcome | Tailored antiplatelet therapy | Dual antiplatelet therapy | difference (% points) (95% CI) | |
|---|---|---|---|---|
| Clinically relevant bleeding · 12 months | 7.2% | Not reported in the abstract | 2.45 (0.37–4.53) | |
| −20246Difference, % points (linear scale) |
- Clinically relevant bleeding: DAPT 4.8%
Original publication
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Eur Heart J. Published 31 August 2025. doi:10.1093/eurheartj/ehaf652
Summarised from the published abstract; every number is checked against it